Is This Stock a Screaming Buy: Recro Pharma, Inc. (NASDAQ:REPH)

Equity Research firms currently have a positive stance on shares of Recro Pharma, Inc. (NASDAQ:REPH). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.50. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $23.67 on a short term basis.

At the time of writing, the stock was trading at $8.18. This represents a change from the opening price of 0.42%. In terms of performance, year to date, the stock is -9.33%. The monthly stock performance comes in at -17.24%. For the quarter, shares are performing at 2.64%. Weekly performance analysis shows the equity at -8.52%.

In taking a look at technical levels, shares are trading -11.40% away from the 50 day simple moving average and 4.54% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -36.36% away from it’s 52- week high and 46.41% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Recro Pharma, Inc.’s RSI stands at 27.64. In looking at volatility levels, the shares saw weekly volatility of 4.35% and 3.07% over the past month.

Leave a Comment